The discovery and development of rivaroxaban

Annals of the New York Academy of Sciences

Volumn 1222, Issue 1, 2011, Pages 64-75

  Misselwitz, Frank ^a   Berkowitz, Scott D ^b   Perzborn, Elisabeth ^a  

^a BAYER PHARMA AG   (Germany)

^b BAYER CORPORATION   (United States)

Author keywords

Anticoagulant; Discovery; Factor Xa; Rivaroxaban

Indexed keywords

ANTISTASIN; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN; RIVAROXABAN; TICK ANTICOAGULANT PEPTIDE;

ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR RISK; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DRUG TARGETING; HUMAN; KNEE ARTHROPLASTY; MORTALITY; NONHUMAN; PATIENT COMPLIANCE; PROPHYLAXIS; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION; VENOUS THROMBOEMBOLISM;

EID: 79952836414     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2011.05971.x     Document Type: Article

References (87)

1. Gailani, D. & T. Renne 2007. Intrinsic pathway of coagulation and arterial thrombosis. Arterioscler. Thromb. Vasc. Biol. 27: 2507-2513.
2. Monroe, D.M. & M. Hoffman 2006. What does it take to make the perfect clot? Arterioscler. Thromb. Vasc. Biol. 26: 41-48.
3. Mann, K.G. 2003. Thrombin formation. Chest 124(Suppl. 3): 4S-10S.
4. Furie, B. & B.C. Furie 2008. Mechanisms of thrombus formation. N. Engl. J. Med. 359: 938-949.
5. Heit, J.A. 2006. The epidemiology of venous thromboembolism in the community: implications for prevention and management. J. Thromb. Thrombolysis 21: 23-29.
6. Kearon, C. 2003. Natural history of venous thromboembolism. Circulation 107: I22-I30.
7. Rosamond, W. et al 2007. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115: e69-e171.
8. Cohen, A.T. et al 2007. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb. Haemost. 98: 756-764.
9. Fowkes, F.J., J.F. Price & F.G. Fowkes 2003. Incidence of diagnosed deep vein thrombosis in the general population: systematic review. Eur. J. Vasc. Endovasc. Surg. 25: 1-5.
10. Cohen, A.T. et al 2008. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 371: 387-394.
11. White, R.H. 2003. The epidemiology of venous thromboembolism. Circulation 107: I4-I8.
12. Kyrle, P.A. et al 2004. The risk of recurrent venous thromboembolism in men and women. N. Engl. J. Med. 350: 2558-2563.
13. Kahn, S.R. & J.S. Ginsberg 2004. Relationship between deep venous thrombosis and the postthrombotic syndrome. Arch. Intern. Med. 164: 17-26.
14. Pengo, V. et al 2004. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N. Engl. J. Med. 350: 2257-2264.
15. Heit, J.A. et al 2001. The epidemiology of venous thromboembolism in the community. Thromb. Haemost. 86: 452-463.
16. Bassand, J.P., I. Richard-Lordereau & Y. Cadroy 2007. Efficacy and safety of fondaparinux in patients with acute coronary syndromes. Expert Rev. Cardiovasc. Ther. 5: 1013-1026.
17. Mackman, N. 2008. Triggers, targets and treatments for thrombosis. Nature 451: 914-918.
18. Ansell, J. 2007. Factor Xa or thrombin: is factor Xa a better target? J. Thromb. Haemost. 5(Suppl. 1): 60-64.
19. Mann, K.G., K. Brummel & S. Butenas 2003. What is all that thrombin for? J. Thromb. Haemost. 1: 1504-1514.
20. Koller, F. 1960. History of Factor X. Thromb. Diath. Haemorrh. 4(Suppl.): 58-65.
21. Brown, D.L. & P.A. Kouides 2008. Diagnosis and treatment of inherited factor X deficiency. Haemophilia 14: 1176-1182.
22. Geerts, W.H. et al 2008. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 133: 381S-453S.
23. Hirsh, J. et al 2008. Parenteral anticoagulants: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 133: 141S-159S.
24. Warkentin, T.E. et al 2008. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 133: 340S-380S.
25. Ansell, J. et al 2008. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 133: 160S-198S.
26. Ansell, J. & D. Bergqvist 2004. Current options in the prevention of thromboembolic disease. Drugs 64(Suppl. 1): 1-5.
27. Hirsh, J., M. O'Donnell & J.I. Weitz 2005. New anticoagulants. Blood 105: 453-463.
28. Weitz, J.I. 2006. Emerging anticoagulants for the treatment of venous thromboembolism. Thromb. Haemost. 96: 274-284.
29. Turpie, A.G.G. 2007. Oral, direct Factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler. Thromb. Vasc. Biol. 27: 1238-1247.
30. Tuszynski, G.P., T.B. Gasic & G.J. Gasic 1987. Isolation and characterization of antistasin. An inhibitor of metastasis and coagulation. J. Biol. Chem. 262: 9718-9723.
31. Dunwiddie, C. et al 1989. Antistasin, a leech-derived inhibitor of factor Xa. Kinetic analysis of enzyme inhibition and identification of the reactive site. J. Biol. Chem. 264: 16694-16699.
32. Waxman, L. et al 1990. Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa. Science 248: 593-596.
33. Nicolini, F.A. et al 1996. Selective inhibition of factor Xa during thrombolytic therapy markedly improves coronary artery patency in a canine model of coronary thrombosis. Blood. Coagul. Fibrinolysis. 7: 39-48.
34. Lynch, J.J., Jr., et al 1994. Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy. A comparison of factor Xa versus thrombin inhibition. Cardiovasc. Res. 28: 78-85.
35. Lefkovits, J. et al 1996. Selective inhibition of factor Xa is more efficient than factor VIIa-tissue factor complex blockade at facilitating coronary thrombolysis in the canine model. J. Am. Coll. Cardiol. 28: 1858-1865.
36. Eisenberg, P.R. et al 1993. Importance of factor Xa in determining the procoagulant activity of whole-blood clots. J. Clin. Invest. 91: 1877-1883.
37. Prager, N.A. et al 1995. Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots. Circulation 92: 962-967.
38. McKenzie, C.R., D.R. Abendschein & P.R. Eisenberg 1996. Sustained inhibition of whole-blood clot procoagulant activity by inhibition of thrombus-associated factor Xa. Arterioscler. Thromb. Vasc. Biol. 16: 1285-1291.
39. Kotze, H.F. et al 1997. Transient interruption of arterial thrombosis by inhibition of factor Xa results in long-term antithrombotic effects in baboons. Thromb. Haemost. 77: 1137-1142.
40. Roehrig, S. et al 2005. Discovery of the novel antithrombotic agent 5-chloro-N-([(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1, 3-oxazolidin-5-yl]methyl)thiophene-2-carboxamide (BAY 59-7939): an oral, direct Factor Xa inhibitor. J. Med. Chem. 48: 5900-5908.
41. Lam, P.Y. et al 2003. Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulants. J. Med. Chem. 46: 4405-4418.
42. Perzborn, E. et al 2005. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 - an oral, direct Factor Xa inhibitor. J. Thromb. Haemost. 3: 514-521.
43. Depasse, F. et al 2005. Effect of BAY 59-7939 - a novel, oral, direct Factor Xa inhibitor - on clot-bound Factor Xa activity in vitro. J. Thromb. Haemost. 3(Suppl. 1): Abstract P1104.
44. Gerotziafas, G.T. et al 2007. In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct Factor Xa inhibitor rivaroxaban. J. Thromb. Haemost. 5: 886-888.
45. Perzborn, E. & M. Harwardt 2008. Direct thrombin inhibitors, but not Factor Xa inhibitors, enhance thrombin formation in human plasma by interfering with the thrombin-thrombomodulin-protein C system. Blood (ASH Annual Meeting Abstracts) 112: 198-199: Abstract 528.
46. Perzborn, E. et al 2004. Biochemical and pharmacologic properties of BAY 59-7939, an oral, direct Factor Xa inhibitor. Pathophysiol. Haemost. Thromb. 33(Suppl. 2): Abstract PO079.
47. Perzborn, E. & U. Lange 2007. Rivaroxaban - an oral, direct Factor Xa inhibitor - inhibits tissue factor-mediated platelet aggregation. J. Thromb. Haemost. 5(Suppl. 2): Abstract P-W-642.
48. Biemond, B.J. et al 2007. Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 59-7939) - an oral, direct Factor Xa inhibitor. Thromb. Haemost. 97: 471-477.
49. Kubitza, D. et al 2005. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin. Pharmacol. Ther. 78: 412-421.
50. Kubitza, D. et al 2005. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - after multiple dosing in healthy male subjects. Eur. J. Clin. Pharmacol. 61: 873-880.
51. Gupta, A., J.D. Unadkat & Q. Mao 2007. Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP). J. Pharm. Sci. 96: 3226-3235.
52. Gupta, A. et al 2004. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). J. Pharmacol. Exp. Ther. 310: 334-341.
53. Kubitza, D. et al 2007. Rivaroxaban (BAY 59-7939) - an oral, direct Factor Xa inhibitor - has no clinically relevant interaction with naproxen. Br. J. Clin. Pharmacol. 63: 469-476.
54. Kubitza, D. et al 2006. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban - an oral, direct Factor Xa inhibitor - are not affected by aspirin. J. Clin. Pharmacol. 46: 981-990.
55. Weinz, C. et al 2005. Pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - in rats and dogs. Xenobiotica 35: 891-910.
56. Lang, D., C. Freudenberger & C. Weinz 2009. In vitro metabolism of rivaroxaban - an oral, direct Factor Xa inhibitor - in liver microsomes and hepatocytes of rat, dog and man. Drug Metab. Dispos. 37: 1046-1055.
57. Weinz, C. et al 2009. Metabolism and excretion of rivaroxaban, an oral, direct Factor Xa inhibitor, in rats, dogs and humans. Drug Metab. Dispos. 37: 1056-1064.
58. Kubitza, D. et al 2008. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr. Med. Res. Opin. 24: 2757-2765.
59. Mueck, W. et al 2008. Population pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct factor Xa inhibitor - in patients undergoing major orthopaedic surgery. Clin. Pharmacokinet. 47: 203-216.
60. Graff, J. et al 2007. Effects of the oral, direct Factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J. Clin. Pharmacol. 47: 1398-1407.
61. Kubitza, D. et al 2007. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J. Clin. Pharmacol. 47: 218-226.
62. Kubitza, D. et al 2010. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban - an oral, direct Factor Xa inhibitor. Br. J. Clin. Pharmacol. 70: 703-712.
63. Halabi, A. et al 2007. Effect of hepatic impairment on the pharmacokinetics, pharmacodynamics and tolerability of rivaroxaban - an oral, direct Factor Xa inhibitor. J. Thromb. Haemost. 5(Suppl. 2): Abstract P-M-635.
64. Kubitza, D., W. Mueck & M. Becka 2008. Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation. Drug Saf. 31: 67-77.
65. Lindhoff-Last, E. et al 2010. Assays for measuring rivaroxaban: their suitability and limitations. Ther. Drug Monit. 32: 673-679.
66. Samama, M.M. et al 2010. An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma. Thromb. Haemost. 104: 1078-1079.
67. Kurtz, S. et al 2007.Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J. Bone Joint Surg. Am. 89: 780-785.
68. Fisher, W.D. et al 2007. Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies. Thromb. Haemost. 97: 931-937.
69. Eriksson, B.I. et al 2006. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 114: 2374-2381.
70. Eriksson, B.I. et al 2008. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N. Engl. J. Med. 358: 2765-2775.
71. Kakkar, A.K. et al 2008. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 372: 31-39.
72. Lassen, M.R. et al 2008. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N. Engl. J. Med. 358: 2776-2786.
73. Turpie, A.G.G. et al 2009. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 373: 1673-1680.
74. Lassen, M.R. et al 2009. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N. Engl. J. Med. 361: 594-604.
75. The RE-MOBILIZE Writing Committee. 2009. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J. Arthroplasty 24: 1-9.
76. Eriksson, B.I. et al 2009. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J. Bone Joint Surg. Br. 91: 636-644.
77. Agnelli, G. et al 2007. Treatment of proximal deep-vein thrombosis with the oral direct Factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (oral direct Factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation 116: 180-187.
78. Buller, H.R. et al 2008. A dose-ranging study evaluating once-daily oral administration of the Factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis. The EINSTEIN-DVT Dose-Ranging Study. Blood 112: 2242-2247.
79. EINSTEIN Investigators, R. Bauersachs, S.D. Berkowitz, B. Brenner, H.R. Buller, H. Decousus, A.S. Gallus, A.W. Lensing, F. Misselwitz, M.H. Prins, G.E. Raskob, A. Segers, P. Verhamme, P. Wells, G. Agnelli, H. Bounameaux, A. Cohen, B.L. Davidson, F. Piovella, S. Schellong 2010. N. Engl. J. Med. Dec 23; 363 (26): 2499-2510.
80. Kearon, C. et al 1999. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N. Engl. J. Med. 340: 901-907.
81. Agnelli, G. et al 2001. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N. Engl. J. Med. 345: 165-169.
82. Agnelli, G. et al 2003. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann. Intern. Med. 139: 19-25.
83. Buller, H.R. 2009. Once-daily oral rivaroxaban versus placebo in the long-term prevention of recurrent symptomatic venous thromboembolism. The Einstein-Extension study. Blood (ASH Annual Meeting Abstracts) 114: Abstract LBA-2.
84. Cohen, A.T. et al 2005. Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thromb. Haemost. 94: 750-759.
85. The Executive Steering Committee on behalf of the ROCKET AF Study Investigators. 2010. Rivaroxaban - once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in atrial fibrillation: rationale and design of the ROCKET AF study. Am. Heart J. 159: 340-347.
86. Rothberg, M.B. et al 2005. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann. Intern. Med. 143: 241-250.
87. Mega, J.L. et al 2009. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 374: 29-38.